Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ron Cohen

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
Nature Biotechnology|November 26, 2020
Supporting US public health expertsRon Cohen, Cedric Francois, John Crowley, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 14, 2015
Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trialsAndrew D Goodman, Francois Bethoux, Theodore R Brown, et al.
The American Journal of Clinical Nutrition|August 14, 2009
Differential functional magnetic resonance imaging response to food pictures in successful weight-loss maintainers relative to normal-weight and obese controlsJeanne M McCaffery, Andreana P Haley, Lawrence H Sweet, et al.
Annals of Neurology|October 27, 2010
A phase 3 trial of extended release oral dalfampridine in multiple sclerosisAndrew D Goodman, Theodore R Brown, Keith R Edwards, et al.
Lancet (London, England)|March 3, 2009
Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trialAndrew D Goodman, Theodore R Brown, Lauren B Krupp, et al.
Clinical Neuropharmacology|August 5, 2003
Pharmacokinetic studies of single and multiple oral doses of fampridine-SR (sustained-release 4-aminopyridine) in patients with chronic spinal cord injuryKeith C Hayes, Patrick J Potter, Robert R Hansebout, et al.
International Journal of Molecular Sciences|May 27, 2023
The Prognostic Value of Anti-PLA2R Antibodies Levels in Primary Membranous NephropathyOlga Lesya Kukuy, Ron Cohen, Boris Gilburd, et al.
The Journal of Pathology|November 26, 2014
Spontaneous bone metastases in a preclinical orthotopic model of invasive lobular carcinoma; the effect of pharmacological targeting TGFβ receptor I kinaseJeroen T Buijs, Kasia M Matula, Henry Cheung, et al.
JAMA|August 26, 2015
Effect of a 24-Month Physical Activity Intervention vs Health Education on Cognitive Outcomes in Sedentary Older Adults: The LIFE Randomized TrialKaycee M Sink, Mark A Espeland, Cynthia M Castro, et al.
Neuroimage. Clinical|November 2, 2013
Disrupted cerebral metabolite levels and lower nadir CD4 + counts are linked to brain volume deficits in 210 HIV-infected patients on stable treatmentXue Hua, Christina P Boyle, Jaroslaw Harezlak, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Nature Biotechnology|November 26, 2020
Supporting US public health expertsRon Cohen, Cedric Francois, John Crowley, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 14, 2015
Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trialsAndrew D Goodman, Francois Bethoux, Theodore R Brown, et al.
The American Journal of Clinical Nutrition|August 14, 2009
Differential functional magnetic resonance imaging response to food pictures in successful weight-loss maintainers relative to normal-weight and obese controlsJeanne M McCaffery, Andreana P Haley, Lawrence H Sweet, et al.
Annals of Neurology|October 27, 2010
A phase 3 trial of extended release oral dalfampridine in multiple sclerosisAndrew D Goodman, Theodore R Brown, Keith R Edwards, et al.
Lancet (London, England)|March 3, 2009
Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trialAndrew D Goodman, Theodore R Brown, Lauren B Krupp, et al.
Clinical Neuropharmacology|August 5, 2003
Pharmacokinetic studies of single and multiple oral doses of fampridine-SR (sustained-release 4-aminopyridine) in patients with chronic spinal cord injuryKeith C Hayes, Patrick J Potter, Robert R Hansebout, et al.
International Journal of Molecular Sciences|May 27, 2023
The Prognostic Value of Anti-PLA2R Antibodies Levels in Primary Membranous NephropathyOlga Lesya Kukuy, Ron Cohen, Boris Gilburd, et al.
The Journal of Pathology|November 26, 2014
Spontaneous bone metastases in a preclinical orthotopic model of invasive lobular carcinoma; the effect of pharmacological targeting TGFβ receptor I kinaseJeroen T Buijs, Kasia M Matula, Henry Cheung, et al.
JAMA|August 26, 2015
Effect of a 24-Month Physical Activity Intervention vs Health Education on Cognitive Outcomes in Sedentary Older Adults: The LIFE Randomized TrialKaycee M Sink, Mark A Espeland, Cynthia M Castro, et al.
Neuroimage. Clinical|November 2, 2013
Disrupted cerebral metabolite levels and lower nadir CD4 + counts are linked to brain volume deficits in 210 HIV-infected patients on stable treatmentXue Hua, Christina P Boyle, Jaroslaw Harezlak, et al.
Pageof 4